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Introduction. Sign and symptoms of rheumatoid arthritis have circadian rhythms and are more prominent in the morning. Timing
of glucocorticoid administration may be important with respect to the natural secretion of endogenous glucocorticoids. Herein,
we intended to test the hypothesis that bedtime administration of prednisolone could be more eﬃcient in controlling signs and
symptoms in patients with RA. Material and Methods. Sixty patients with stable disease were treated with single dose prednisolone
at 8 a.m. for the ﬁrst three months and thereafter with similar dose at 10PM for the next three months (before-after method).
We compared fatigue scores, morning stiﬀness and pain scores, Clinical Disease Activity Indices, erythrocyte sedimentation
rates, C Reactive Protein, and proﬁle of adverse eﬀects. Results. The mean of morning stiﬀness, fatigue scores, CRP and CDAI
decreased statistically when prednisolone was administrated at 10p.m. The means of pain scores and ESR were also decreased
when the patients took prednisolone at night, without signiﬁcant statistical diﬀerence. Conclusion. Administration of low-dose
oral prednisolone could reduce disease activity scores in morning in clinically stable patients with RA. So it could be supposed that
administrating bedtime prednisolone may permit the smallest possible dose.
1.Introduction
In rheumatoid arthritis (RA), a circadian rhythm of disease
activity has been well documented [1]. Morning stiﬀness,
joint pain, and swelling (one of the RA classiﬁcation criteria)
are worse in morning, which could be explained by diurnal
variations in the metabolism or secretion of endogenous
cortisol and cytokines, especially IL6 [2]. Corticotropin-
releasing hormone (CRH) release leads to the pituitary
production of corticotrophin (ACTH), followed by gluco-
corticoid secretion by the adrenal cortex. These components
constitute the hypothalamic-pituitary-adrenocortical (HPA)
axis, which has a circadian rhythm [3]. The ACTH level
varies during the day due to its pulsatile secretion. As a
result, in physiologic conditions, plasma ACTH and serum
cortisol concentrations are highest at about the time of
waking in the morning (at 8 AM), decrease irregularly
during the day, are low in the evening, and reach their
nadir after beginning sleep (at 2 AM) [4]. In RA patients,
impaired cortisol secretion to ACTH has been described,
supporting the concept of a relative adrenal glucocorticoid
insuﬃciency [5]. Moreover, IL6 is also considered to be
responsible for stimulating the production of acute phase
of proteins, and increased levels of it have been reported in
serum and synovial ﬂuid in RA. Increased levels of IL6 were
found from 2 AM to 7 AM in RA patients, which has been
associated with a ﬂare in disease activity in early morning
[6, 7]. Therefore, diurnal variations in the clinical signs and
symptoms of RA may be partly due to changes in the cortisol
and proinﬂammatory cytokine levels.
Glucocorticoids (GCs) are among the most frequently
used drugs in treating RA, and most commonly are used
to suppress inﬂammation and pain. This eﬀect is brought
about by their anti-inﬂammatory and immunosuppressive
properties [8]. But HPA axis support is a crucial rule of low-
dose GCs in stable RA.
When a potentially harmful drug such as a GC is
prescribed, a balance between side eﬀects and therapeutic2 ISRN Pharmacology
Table 1: Characteristics of the patients at initiation of study.
Age (year) (mean ± SD) 20–67 (46 ± 11.09)
Female/male 51/9
Duration of disease (year) (mean ± SD) 1–40 (7.1 ± 7.5)
Number of involved joints (mean ± SD) 0–8 (4.1 ± 1.78)
Mean of fatigue score 2–8 (4.6 ± 1.90)
Mean of pain score 0–2 (1.18 ± 0.46)
Mean of morning stiﬀness score 1–3 (1.91 ± 0.67)
Mean of ESR 3–60 (24.11 ± 14.01)
Mean of CRP 6–24 (11.37 ± 8.31)
Mean of CDAI 4–9 (6.56 ± 1.35)
Mean of prednisolone dose 5–7.5 (5.125 ± 0.549)
CDAI: Clinical Disease Activity Indices, ESR: erythrocyte sedimentation
rate, CRP: C-reactive protein.
Table 2: Proﬁle of DMARDs used in the patients.
DMARDs Number (percent)
HCQ or SSZ or MTX 13 (21.7)
HCQ + MTX 32 (53.3)
MTX + SSZ 4 (6.7)
HCQ + SSZ 1 (1.7)
MTX + HCQ + CsA 1 (1.7)
MTX + SSZ + CsA 1 (1.7)
MTX + SSZ + HCQ 8 (13.3)
MTX: methotrexate, HCQ: hydroxychloroquine, SSZ: sulfasalazine, CsA:
cyclosporine A.
beneﬁts is attempted, and it is prudent to administer the
minimal dose for the shortest duration to avoid adverse
eﬀects [9]. With assumption of minimizing interference with
the normal diurnal hormonal pattern, in usual practice, in
single-dose schedule, prednisolone is administered in the
morning. It seems that administration of prednisolone at
bedtime, which precedes the circadian ﬂare of inﬂammatory
activity, can potentially better control disease activity in
somewhat lower doses [10].
In order to reduce the chance of HPA suppression, we
should use the lowest dose of short half-life GCs, preferably
in alternate fashion. Accordingly, using the drug at the
optimal time may permit the smallest possible dose to be
used. Prescribing GCs at night may in part lead to the
suppression of an explosive surge of cytokines between 2
AM and 7 AM by better HPA axis support, so it is assumed
that when a low dose GC is used for relief of morning
stiﬀness, night administration could be more eﬀective than
an equivalent dose given in the morning [5].
In this study, we decided to test the hypothesis that
administration of low-dose prednisolone at bedtime could
be more eﬀective in control of disease activity and morning
symptoms.
2.MaterialandMethods
Sixty patients who fulﬁlled the criteria of the 2010 American
College of Rheumatology [11] for RA were included in
this study from April to September 2008. All patients
were referred to the Yazd Rheumatology Center and were
studied after obtaining informed consents and approval of
the local ethics committee according to the Declaration
of Helsinki. At the start of the study, all of the patients
had been on long treatment with a single daily dose
of prednisolone (≤7.5mg/day) and one or more disease
modifying antirheumatic drugs (DMARDs).
Those who were taking drugs other than nonsteroidal
anti-inﬂammatory drugs (NSAIDs) and DMARDs and those
with any comorbid conditions such as diabetes, hyperten-
sion, and other chronic diseases were excluded.
5mg prednisolone was reinstituted for the patients in the
morning (8 AM) for the ﬁrst three months, and, for the next
three months, the patients received 5mg prednisolone at 10
PM (before-after method). No change in the DMARDs was
scheduledduringthestudy.Patientstooktheirdrugat10PM
to prevent interference with their sleep.
A questionnaire including age, gender, the number of
involved and tender joints, pain score (none = 0, mild = 1,
moderate = 2, severe = 3), fatigue score (none = 0, mild = 1–
3, moderate = 4–6, severe = 7–10), morning stiﬀness score (0
= none, 1 ≤ 30min, 2 = 30–60min, 3 = 1-2h, 4 = 2–4h, 5 ≥
4hand6=allday),erythrocytesedimentationrates(ESR),C
reactive protein (CRP), and supposed adverse eﬀects proﬁle
of tachycardia, nocturia, sleep disturbance, infection, and
blood pressure disturbance was designed by the authors on
the basis of similar studies. ESR and CRP were measured at
the beginning of the study and end of the ﬁrst and second
trimester. The clinical data were collected at the end of each
month during the study.
We used the Clinical Disease Activity Index (CDAI) [12],
a numerical index that is calculated by summing the number
of tender and swollen joints using the 28-joint count and the
patient and physician global assessments on a 10cm visual
analoguescale.TheCDAIrangesfrom0to76.Thecutpoints
for remission and various degrees of disease activity are as
follows:
(i) remission ≤ 2.8,
(ii) low disease activity ≤ 10,
(iii) moderate disease activity ≤ 22,
(iv) high disease activity > 22.
Means of each variable within the ﬁrst and second trimester
a n da tt h ee n do fe a c ht r i m e s t e rw e r ec o m p a r e d .
3.StatisticalAnalysis
Data are presented as mean ± standard deviation of the
mean. Statistical signiﬁcance was calculated by nonparamet-
ric Wilcoxon’s signed ranks test using SPSS version 11.5
(SPSS Inc., Chicago, IL, USA) for Windows. A P value < 0.05
was considered as signiﬁcant diﬀerence.
4. Results
Sixty patients, nine male (15%) and ﬁfty-one female (85%),
with a mean age of 46 ± 11.09, were included in theISRN Pharmacology 3
Table 3: Comparison of mean of variables between two groups.
Variable Morning group ± SD (min–max) Bedtime group ± SD (min–max) P valuea
Fatigue scoreb 4.58 ± 1.87(1–8) 3.58 ± 2.17(0–7) 0.000
Pain scorec 1.000 ± 0.52(0–2) 0.88 ± 0.52(0–2) 0.146
Morning stiﬀness scored 1.81 ± 4.28(0–3) 1.03 ± 2.92(0–2) 0.000
CDAIe 6.4 ± 2.7(3–7) 4.07 ± 2.18(3–5) 0.000
CDAI: Clinical Disease Activity Indices aP < 0.05 is signiﬁcant.
b( n o n e :0 ,l o wg r a d e :1 ,h i g hg r a d e :2 . )
c(none=0, mild: 1, moderate: 2, severe: 3.)
d(0: none, 1: ≤30min, 2: 30-60min, 3: 1-2h, 4: 2-4h, 5: ≥4hand6:allday .)
e(Remission ≤ 2.8, low disease activity ≤ 10, moderate disease activity ≤ 22, high disease activity > 22.)
Table 4: Comparison between variable at the third and sixth month. (end month of each trimester).
Variable Morning group ± SD (min–max) Bedtime group ± SD(min–max) P value
Fatigue score 4.37 ± 1.44 (2–7) 2.57 ± 1.00 (1–6) <0.0001
Morning stiﬀness score 0.77 ± 0.33 (1–3) 0.74 ± 0.51 (1–3) 0.0003
CDAI 6.20 ± 1.87 (4–8) 4.02 ± 2.00 (3–7) <0.0001
Pain score 0.85 ± 0.55 (0–2) 0.82 ± 0.54 (0–2) 0.7367
CRP (mg/dl) 7.6 ± 0.93 (6–26) 6.4 ± 0.76 (6–23) 0.04
ESR (mm/h) 18 ± 11.56 (1–56) 17 ± 8.93 (2–40) 0.283
ESR: erythrocyte sedimentation rate; CRP: C reactive protein.
Table 5: Comparison between adverse eﬀects in two groups.





Nocturia No 3 (5%)
Sleep disturbance No 1 (0.016%)
BP disturbance 2 (0.03%) No
Tachycardia 2 (0.03%) 2 (0.03%)
Overt infection No No
study. Baseline characteristics of the patients are shown in
Table 1. Disease duration among our patients was between
12 months to 40 years with mean of 7.1 ± 7.5y e a r sa s
mentioned in Table 1. But they were on DMARDs from
beginning of disease in some and months after initiation of
disease in the others. Minimum duration of DMARD used
in our patient when they enrolled in the study was around 6
months.Thirty-sevenpatients(53.3%)weretreatedwithtwo
DMARDs, and ten (16.7%) patients were treated with three
DMARDs (Table 2).
The mean of the morning stiﬀness was decreased and
had signiﬁcant statistical diﬀerences (P value = 0.000). The
mean of the CDAI was reduced at the end of the second three
months, when the patients were treated with prednisolone
at night (P value = 0.000). The mean of the fatigue score
and CRP level were decreased when prednisolone was
administrated at 10 PM, and diﬀerences were signiﬁcant (P
value < 0.05). The mean of the pain score was decreased
when the patients took prednisolone at night, but there was
no signiﬁcant statistical diﬀerence (P value = 0.146). Also,
the mean of tender joint was decreased when the patient
took prednisolone at nigh; however, there was no signiﬁcant
statistical diﬀerence (P value = 0.129). The mean of the ESR
was decreased, but the diﬀerence was not signiﬁcant (P value
= 0.283). These data are compared in Table 3.
Means of each variable at the end of the ﬁrst and the
second trimester are compared in Table 4.
Nocturia was seen in 3 patients (5%) when prednisolone
was administrated at night, and sleep disturbance was seen
in 1 patient in this group (Table 5).
InFigure 1,comparisonofvariablemeansatbaselineand
end of before and after phase was shown.
5. Discussion
Better control of inﬂammation and improving patient
symptoms related to inﬂammatory state with minimal drug
adverse eﬀect is the best management in chronic inﬂamma-
tory conditions like RA.
In the current study, administration of prednisolone at
night induced a signiﬁcant beneﬁcial eﬀect on the morning
stiﬀness (P<0.001), which was similar to the results of the
Arvison [8] and Buttgereit report [13]. It should be stated
that in the Arvidson study, prednisolone was taken at 2 AM,
which could potentially have a negative eﬀect on the sleep
pattern of patients [8]. De Silva et al. showed a signiﬁcantly
shorter duration of morning stiﬀness in patients when
prednisolone was given at night [14]. Similar to our study,
the patients were on oral prednisolone at 10 PM Deandrade
et al. also noted that a small evening dose was more eﬀective
than the same dose given in the morning [15]. Klinefelter
and his coworkers evaluated the safety of single low-dose
prednisone therapy. In their study, a number of patients
required nocturnal doses to control their morning stiﬀness
and did not show any more suppression of the HPA axis

















Fatigue is frequently identiﬁed as a signiﬁcant symptom
by RA patients [17]. The prevalence of clinically relevant
fatigue is commonly seen between 40% and 80% of patients
with RA [18]. We showed that the mean of fatigue scores
also decreased when the prednisolone was administrated at
night (P<0.000). However, this variable was not taken into
consideration in the previous studies, although it is a main
complaint of patients.
The theoretical optimal timing of prednisolone admin-
istration could be at 2 AM but due to interfering with pre-
disturbedsleepinRApatients,modiﬁedreleaseprednisolone
was introduced to overcome this problem. We, in our study,
showed that shifting single oral prednisolone from morning
to bedtime schedule also could have similar beneﬁcial eﬀect
on morning symptom which is universally available.
In our patients, there was a tendency for a decrease in
the mean of pain scores when the patients took prednisolone
at night, although employing Wilcoxon’s test showed no
statistical signiﬁcant diﬀerence. Result of means of variables
was similar within and at the end of each trimester.
However, in the study conducted by Arvidson [8]a n d
Buttgereit [13], pain scores decreased statistically signiﬁcant
after bedtime administration of GCs.
Inanotherstudy,clinicaloutcomeafteradministrationof
prednisolone at 8 AM, 1 PM and 11 PM was compared. Four
weeks later, there was no diﬀerence in pain or stiﬀness scores
between these times of prednisolone administration [19].
Also, Karatay and his colleagues reported that there were
no diﬀerences between pain and morning stiﬀness scores
when GCs were administered at diﬀerent times of the day
[20].Thediﬀerencesbetweenourandtheirﬁndingscouldbe
attributed to the total daily doses and/or ethnic diﬀerences in
the patients.
A comparison of objective measurements of joint
inﬂammation revealed no signiﬁcant statistical diﬀerences,
although there was a decline in the number of tender joints.
Nevertheless, it should be mentioned that in most of our
patients, joint tenderness was not a predominant symptom.
In our study, CDAI was also used for clinical assessment
and there was a signiﬁcant statistical diﬀerence between the
mean of two groups.
In spite of a reduction in the mean of ESR, there was
no signiﬁcant statistical diﬀerence (P = 0.283). As in the
studies done by Arvidson et al. and Karatay et al., the mean
of CRP levels decreased signiﬁcantly following nocturnal use
of prednisolone [8, 20].
We emphasized that adverse proﬁle of shifting pred-
nisolone from morning to bedtime was negligible in our sur-
vey and none of them was related to HPA axis derangement.
Addressing to our limitations in the study, we should
mention that, due to clinical nature of our study we did not
determine the cytokines such as IL6 and hormones involving
in HPA axis notably serum and urine cortisol that it could
be designed as a separate supplementary study. Also, we
think that due to potential beneﬁcial of bedtime dosing of
prednisolone, we could test smaller doses of prednisolone
at bedtime along with this study and compare the mean of
prednisolone doses in two phases (groups) of study.
6. Conclusion
In conclusion, our study showed that similar doses of
prednisolone could be safely administrated at bedtime with
better clinical responses in most (but not all) of RA patients.
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